Skip to main content Skip to search Skip to main navigation

FDA: New FDA Commissioner Dr. Heidi Overton

President Donald Trump has named White House aide Heidi Overton to lead the US Food and Drug Administration (FDA). Overton will fill the position previously held by Marty Makary, who left the agency in May. This announcement was made on Trump's Truth Social account on 19 August. Her nomination is subject to confirmation by the Senate.

Overton is currently deputy director of the White House Domestic Policy Council. Previously, she served as chief policy officer and vice chair of the Center for a Healthy America at AFPI (America First Policy Institute). Before joining AFPI, Overton was a general surgery resident at Johns Hopkins University, where she also obtained a PhD in clinical investigation. 

Scott Whitaker, president and CEO of the Advanced Medical Technology Association (AdvaMed) said the group supports the nomination. 

“We look forward to continuing our work with FDA under Dr. Overton’s leadership if she is confirmed by the Senate. As a medical doctor with a background in public health, she has a deep understanding of the critical role medical technology plays in lowering cost and improving patient outcomes. The transformative nature of medtech helps ensure that patients are in control of their own health and doctors are empowered to treat patients with the most innovative technologies. It is essential that we continue the progress we have made to ensure that transparency, consistency, and predictability remain the hallmarks of the review process at CDRH.

President Trump wrote on Truth Social: “She is known to take on the HARDEST issues, and bring me solutions that work best for the Country….We need her leadership at the FDA now.”


Source:

FDA: Trump taps Heidi Overton as next FDA Commissioner

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

Applying the FDA’s 7-Step Model for AI/ML Validation in GMP Environments: One Year Later

Applying the FDA’s 7-Step Model for AI/ML Validation in GMP Environments: One Year Later

Artificial intelligence is becoming increasingly important in GMP-regulated environments, presenting companies with new regulatory challenges. This article summarizes the latest regulatory developments, introduces a validation framework based on the FDA's seven-step model, and outlines initial practical experience with AI/ML validation.

Read more
Question of the Week | GMP-Verlag

What are the General Requirements for Standard Documents?

Here's the answer:
Read more
News: Europe

EDQM: Revised Guidance on Sister File Applications

The European Directorate for the Quality of Medicines & HealthCare (EDQM) has revised its Guidance on applications for “sister files” (PA/PH/CEP (09) 141). The revision is intended to support consistent application of the procedure and provide greater clarity on the classification and assessment of the corresponding CEP applications.
Read more
Swissmedic Clarifies Requirements for QR Codes on Medicinal Product Packaging

Swissmedic Clarifies Requirements for QR Codes on Medicinal Product Packaging

Swissmedic has revised its guidance document “Mobile technologies” and added two new entries to the related questions and answers. The update follows an increasing number of queries regarding the details and placement of URLs, the positioning of QR codes and their captions.
Read more
News: EMA

EMA: Withdrawal of an Application due to Missing Confirmation of a Manufacturing Site’s GMP Status

EMA reported that Scholar Rock Netherlands withdrew its application for Isembyld after evaluation had progressed through the final round of questions. EMA’s provisional view was that the medicine could not be authorised because the applicant had not provided confirmation that the manufacturing site complied with EU GMP requirements.

Read more
News: Europe

France: ANSM Launches Pilot Project to Extend the Shelf Life of Medicines

The French medicines agency ANSM has published an update on its “Longue vie aux médicaments” pilot project aimed at extending the shelf life of medicines. Fourteen pharmaceutical companies responded to the call for applications. The project covers a total of 73 medicines, including commonly used products containing paracetamol, levothyroxine, melatonin or lithium.
Read more
Previous
Next